Matches in DBpedia 2016-04 for { ?s ?p "Generic Pharmaceutical Price Decay is what happens (in the UK) once the originator brand has lost its patent exclusivity (patent expiry) and generic versions of the originator brand have been launched. The number of license holders entering the market is controlled by the ease of manufacture and the number of companies making the active pharmaceutical ingredient (API). For many easy-to-manufacture solid dose tablets and capsules the manufacturing is done in India and China as the costs of production in these countries is significantly lower than in the US or Europe.On day one of generic launch the first to market the generic product usually gets more market share than late entrants. Both manufacturers (who make their own generic products) and license only holders (who use other companies to do the manufacturing) may be represented.If only one company is able to release a generic product into the UK market, the discount against the originator brand is likely to be small, and the price will usually follow the same trend as the brand price. However in most cases more than one company will release stock at launch and they will compete for market share with other manufacturers and license holders. This means persuading chemists and dispensing doctors to purchase stock. As competition drives the price of the generic product down, the average price in the market typically follows a scalloped curve which will decline with time at a rate that is driven by the numbers of license holders and manufacturers.Changes in the reimbursement price Drug Tariff will also serve to suppress this curve even more.Generic substitution was planned for the England, but this was rejected in late 2010. Generic substitution would have meant that a prescription written for a branded product by a doctor would result in a pharmacist giving the patient a generic medicine. On Thursday 14 October, the UK's Department of Health announced that it would not be proceeding with the proposals to implement generic substitution. Patient safety was cited as the primary reason for the rejection of this policy.In the case of more complex products, such as creams, inhalers and injectables, generic prices decay at a slower rate as fewer companies are able to make the product.In the UK, the M category of the Drug Tariff (reimbursement prices) is used to control the profits of chemists and to reduce the UK's health care tax burden.The rate of decay of most generic solid dose products has been shown to follow a predictable path and to have some similarity to the decay in price of other non pharmaceutical products.Eventually price decline comes to and end and the price flattens out at approximately 20% of the original brand price."@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- Generic_Pharmaceutical_Price_Decay abstract "Generic Pharmaceutical Price Decay is what happens (in the UK) once the originator brand has lost its patent exclusivity (patent expiry) and generic versions of the originator brand have been launched. The number of license holders entering the market is controlled by the ease of manufacture and the number of companies making the active pharmaceutical ingredient (API). For many easy-to-manufacture solid dose tablets and capsules the manufacturing is done in India and China as the costs of production in these countries is significantly lower than in the US or Europe.On day one of generic launch the first to market the generic product usually gets more market share than late entrants. Both manufacturers (who make their own generic products) and license only holders (who use other companies to do the manufacturing) may be represented.If only one company is able to release a generic product into the UK market, the discount against the originator brand is likely to be small, and the price will usually follow the same trend as the brand price. However in most cases more than one company will release stock at launch and they will compete for market share with other manufacturers and license holders. This means persuading chemists and dispensing doctors to purchase stock. As competition drives the price of the generic product down, the average price in the market typically follows a scalloped curve which will decline with time at a rate that is driven by the numbers of license holders and manufacturers.Changes in the reimbursement price Drug Tariff will also serve to suppress this curve even more.Generic substitution was planned for the England, but this was rejected in late 2010. Generic substitution would have meant that a prescription written for a branded product by a doctor would result in a pharmacist giving the patient a generic medicine. On Thursday 14 October, the UK's Department of Health announced that it would not be proceeding with the proposals to implement generic substitution. Patient safety was cited as the primary reason for the rejection of this policy.In the case of more complex products, such as creams, inhalers and injectables, generic prices decay at a slower rate as fewer companies are able to make the product.In the UK, the M category of the Drug Tariff (reimbursement prices) is used to control the profits of chemists and to reduce the UK's health care tax burden.The rate of decay of most generic solid dose products has been shown to follow a predictable path and to have some similarity to the decay in price of other non pharmaceutical products.Eventually price decline comes to and end and the price flattens out at approximately 20% of the original brand price.".
- Q5532656 abstract "Generic Pharmaceutical Price Decay is what happens (in the UK) once the originator brand has lost its patent exclusivity (patent expiry) and generic versions of the originator brand have been launched. The number of license holders entering the market is controlled by the ease of manufacture and the number of companies making the active pharmaceutical ingredient (API). For many easy-to-manufacture solid dose tablets and capsules the manufacturing is done in India and China as the costs of production in these countries is significantly lower than in the US or Europe.On day one of generic launch the first to market the generic product usually gets more market share than late entrants. Both manufacturers (who make their own generic products) and license only holders (who use other companies to do the manufacturing) may be represented.If only one company is able to release a generic product into the UK market, the discount against the originator brand is likely to be small, and the price will usually follow the same trend as the brand price. However in most cases more than one company will release stock at launch and they will compete for market share with other manufacturers and license holders. This means persuading chemists and dispensing doctors to purchase stock. As competition drives the price of the generic product down, the average price in the market typically follows a scalloped curve which will decline with time at a rate that is driven by the numbers of license holders and manufacturers.Changes in the reimbursement price Drug Tariff will also serve to suppress this curve even more.Generic substitution was planned for the England, but this was rejected in late 2010. Generic substitution would have meant that a prescription written for a branded product by a doctor would result in a pharmacist giving the patient a generic medicine. On Thursday 14 October, the UK's Department of Health announced that it would not be proceeding with the proposals to implement generic substitution. Patient safety was cited as the primary reason for the rejection of this policy.In the case of more complex products, such as creams, inhalers and injectables, generic prices decay at a slower rate as fewer companies are able to make the product.In the UK, the M category of the Drug Tariff (reimbursement prices) is used to control the profits of chemists and to reduce the UK's health care tax burden.The rate of decay of most generic solid dose products has been shown to follow a predictable path and to have some similarity to the decay in price of other non pharmaceutical products.Eventually price decline comes to and end and the price flattens out at approximately 20% of the original brand price.".